Pharmaceuticals News and Research

RSS

Patients with genotype 1 chronic HCV infection achieve high SVR rates with VIEKIRAX + EXVIERA

AbbVie, a global biopharmaceutical company, today announced data showing that patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection who received the recommended regimen of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets), with or without ribavirin (RBV), achieved high sustained virologic response rates at 48 weeks post-treatment (SVR48), regardless of the presence of baseline resistance-associated variants (RAVs).

15 Apr 2016

SU2C Catalyst program to accelerate research on cancer prevention, detection and treatment

Stand Up To Cancer, the charitable initiative aimed at bringing new treatments to cancer patients quickly, today announced Catalyst, a new program that will use funding and materials from the pharmaceutical, biotechnology, diagnostic and medical devices industries to accelerate research on cancer prevention, detection and treatment.

14 Apr 2016

Pluristem granted two key cell therapy patents in Japan

Pluristem Therapeutics Inc. (PSTI), a leading developer of placenta-based cell therapy products, has announced that the Japan Patent Office has granted the Company two key patents addressing...

14 Apr 2016

Innate Immunotherapeutics announces clinical trial fully enrolled and receives strong interest from potential Pharma partners

Innate Immunotherapeutics Limited has closed enrolment into the Company's Phase 2B placebo controlled efficacy trial of MIS416 in patients with secondary progressive multiple sclerosis (SPMS). The study has exceeded the original recruitment target of 90 subjects with the successful enrolment this week of the 93rd patient.

14 Apr 2016

UC San Diego receives NIH grant to establish interdisciplinary center to combat antibiotic resistance

Researchers at University of California, San Diego School of Medicine have received a five-year, $9.5-million award from the National Institute of Allergy and Infectious Diseases at the National Institutes of Health to establish an interdisciplinary center to define the systems biology of antibiotic resistance. The program will be led by Bernhard Palsson, PhD, Distinguished Professor of Bioengineering and Pediatrics, and Victor Nizet, MD, professor of pediatrics and pharmacy.

13 Apr 2016

Study reveals TRPV2 protein as new target for chronic pain, cancer treatments

In a recent paper published in Nature Communications, a group of Case Western University School of Medicine researchers presented their discovery of the full-length structure of a protein named Transient Receptor Potential Vanilloid subtype 2 (TRPV2).

13 Apr 2016

RedHill Biopharma initiates phase II study of BEKINDA for irritable bowel syndrome

RedHill Biopharma Ltd. (NASDAQ; RDHL) (TASE: RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced that it has initiated a randomized, double-blind, 2-arm parallel group Phase II clinical study in the U.S. evaluating the safety and efficacy of BEKINDA™ 12 mg in patients with diarrhea-predominant irritable bowel syndrome (IBS-D).

13 Apr 2016

University’s blindness therapy comes a step closer following landmark licensing deal with US firm

Hundreds of thousands of people worldwide, who have a disease that can lead to blindness, could have their sight restored after The University of Manchester entered into a technology license with Seattle-based company Acucela Inc.

13 Apr 2016

University's blindness therapy comes a step closer following landmark licensing deal with US firm

13 Apr 2016

Novel antibiotics to overcome antibacterial resistance

Small and innovative pharmaceutical companies, with products in early stages of development, presented some of their novel approaches and antimicrobial therapies under development during a dedicated session at the annual congress (ECCMID) of the European Society of Clinical Microbiology and Infectious Diseases(ESCMID) in Amsterdam.

13 Apr 2016

$New sensitive detection method could help measure subfractions of HDL$

New sensitive detection method could help measure subfractions of HDL

High-density lipoprotein (HDL) is often referred to as good cholesterol: high levels of HDL are associated with lower risk of cardiovascular disease. But many clinical outcome trials for drugs that raise HDL levels have failed to show significant benefits for trial participants.

12 Apr 2016

Pooled analysis from seven clinical studies demonstrates consistent efficacy for ceftazidime-avibactam in the treatment of multi-drug resistant gram-negative bacteria

AstraZeneca has presented positive data demonstrating the efficacy of the investigational antibiotic, ceftazidime-avibactam (CAZ-AVI), in treating patients with ceftazidime-resistant Gram-negative infections, which are increasingly resistant to most available antibiotics, often precipitating the need for clinicians to reach for agents previously reserved for last-line use.

12 Apr 2016

Ariste Medical develops drug-eluting mesh for more effective open hernia repair

Ariste Medical has revealed new research outlining the company’s novel method for addressing medical device failure in open ventral hernia repair.

12 Apr 2016

High–performance, cost-effective NMR solutions for the pharmaceutical and chemical industries

At the 57th Experimental Nuclear Magnetic Resonance Conference (www.enc-conference.org), Bruker is showcasing several innovative drug discovery, drug development and process control solutions for small molecule NMR characterization in the chemical and pharmaceutical industries.

From Bruker BioSpin Division 11 Apr 2016

New GHz-class NMR magnet and probe technologies introduced by Bruker at ENC 2016

At the 57th Experimental Nuclear Magnetic Resonance Conference (www.enc-conference.org), Bruker announced new GHz-class NMR magnet and probe technologies to enable expanding frontiers in structural biology, membrane protein and intrinsically disordered protein (IDP) research.

From Bruker BioSpin Division 11 Apr 2016

Added benefit of crizotinib drug for first-line treatment of advanced bronchial carcinoma not proven

The drug crizotinib (trade name: Xalkori) has been available since 2012 for patients with advanced non-small cell lung cancer (bronchial carcinoma) who have a high activity of the enzyme anaplastic lymphoma kinase (ALK) and have already received another treatment. In November 2015, the approval was extended to first-line treatment.

11 Apr 2016

Ludwig, CRI launch Phase 1/2 trial of combination immunotherapy for advanced ovarian cancer

Ludwig Cancer Research and the Cancer Research Institute have launched a Phase 1/2 clinical trial of combination immunotherapy for advanced ovarian cancer. The international, multicenter trial is led by George Coukos, director of the Ludwig Institute for Cancer Research, Lausanne and Brad Monk, director of Gynecologic Oncology at St. Joseph's Hospital and Medical Center.

7 Apr 2016

SCIEX and QPS Holdings enter collaboration to establish the BioBA solution for bioanalysis of biologics

SCIEX, a global leader in life science analytical technologies, and QPS Holdings, LLC (QPS), a leading global full-service Contract Research Organization (CRO), today announced a collaboration to advance Hybrid LBA –LCMS, a workflow for routine biologics quantification. Under the agreement, QPS Holdings will deploy the SCIEX BioBA Solution, the first end-to-end and most complete solution for bioanalysis of biologics.

6 Apr 2016

AXT expands preclinical imaging portfolio with addition of inviCRO’s innovative software platforms

AXT has recently bolstered their preclinical and translational imaging products portfolio with the addition of inviCRO’s innovative software platforms.

From AXT Pty Ltd 5 Apr 2016

SymCel joins global initiative to combat antibiotic resistance

Following the global and joint initiative by the pharmaceutical, biotechnology and diagnostics industries this year to combat antibiotic resistance, demand for innovative solutions is especially high. The event took place in January at the World Economic Forum in Davos.

5 Apr 2016

Pharmaceuticals News and Research

Patients with genotype 1 chronic HCV infection achieve high SVR rates with VIEKIRAX + EXVIERA

SU2C Catalyst program to accelerate research on cancer prevention, detection and treatment

Pluristem granted two key cell therapy patents in Japan

Innate Immunotherapeutics announces clinical trial fully enrolled and receives strong interest from potential Pharma partners

UC San Diego receives NIH grant to establish interdisciplinary center to combat antibiotic resistance

Study reveals TRPV2 protein as new target for chronic pain, cancer treatments

RedHill Biopharma initiates phase II study of BEKINDA for irritable bowel syndrome

University’s blindness therapy comes a step closer following landmark licensing deal with US firm

University's blindness therapy comes a step closer following landmark licensing deal with US firm

Novel antibiotics to overcome antibacterial resistance

New sensitive detection method could help measure subfractions of HDL

Pooled analysis from seven clinical studies demonstrates consistent efficacy for ceftazidime-avibactam in the treatment of multi-drug resistant gram-negative bacteria

Ariste Medical develops drug-eluting mesh for more effective open hernia repair

High–performance, cost-effective NMR solutions for the pharmaceutical and chemical industries

New GHz-class NMR magnet and probe technologies introduced by Bruker at ENC 2016

Added benefit of crizotinib drug for first-line treatment of advanced bronchial carcinoma not proven

Ludwig, CRI launch Phase 1/2 trial of combination immunotherapy for advanced ovarian cancer

SCIEX and QPS Holdings enter collaboration to establish the BioBA solution for bioanalysis of biologics

AXT expands preclinical imaging portfolio with addition of inviCRO’s innovative software platforms

SymCel joins global initiative to combat antibiotic resistance

Pittcon Highlights: Pharmaceutical & Biologic eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring